Abstract
BackgroundHuman epidermal growth factor receptor 2 (HER2) targeted antibodies in combination with chemotherapy has improved outcomes of HER2 positive (pos) breast cancer (BC) but toxicity of therapy remains a problem....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have